Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Cellular senescence in cancer treatment: friend or foe?

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
589kB

Official URL:https://doi.org/10.1172/JCI20784
PubMed:View item in PubMed
Creators Name:Kahlem, P. and Doerken, B. and Schmitt, C.A.
Journal Title:Journal of Clinical Investigation
Journal Abbreviation:J Clin Invest
Volume:113
Number:2
Page Range:169-174
Date:January 2004
Keywords:Antineoplastic Agents, Apoptosis, Cell Aging, Tumor Cell Line, Cyclin-Dependent Kinase Inhibitor p16, DNA, DNA Damage, Biological Models, Neoplasms, Tumor Suppressor Protein p53, Animals
Abstract:Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
ISSN:0021-9738
Publisher:American Society for Clinical Investigation (U.S.A.)
Item Type:Article

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library